April 23, 2017 | SteadyMed Therapeutics, an Israeli medical company, raised $30 million in a private placement led by Adage Capital Management, OrbiMed, Deerfield Management and Kingdon Capital Management. SteadyMed develops drug product candidates to treat orphan and high-value diseases with unmet delivery needs. The company was founded in 2005 in the Zisapel family’s RAD Biomed incubator. Headquartered in San Ramon, California, much of the company’s development is carried out in its Rehovot offices. In 2015, the company raised $40 million on Nasdaq and last year raised $32 million in a private placement.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments